nivolumab,ipilimumab
ono Pharmaceuticals,bms
['nivo', 'checkmate 358', 'medsir']
safety and efficacy results of phase 1/2 checkmate 358 study showed chemo-free dual immunotherapy nivo+ipi regimens can provide meaningful and durable response with manageable toxicity in recurrent/metastatic cervical cancer regardless of pd l1 status. big talk #esmo22 
Bring your idea to life??Creating successful IITs & optimal drug development??Medica Scientia Innovation Research????????https://t.co/cciUf0lqpM